The Servier deal removes the muscular dystrophy pipeline risk and provides a massive cash infusion, but the company is now a single-asset cardiovascular biotech with no approved products. The key catalyst is the Phase 3 start for EDG-7500 in HCM in Q4 2026. Monitor for milestone payments from Servier (up to $1.1B) and any early efficacy/safety signals from the EDG-7500 Phase 3 program.
Drugs in focus
EWTX drug pipeline →EDG-15400
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
- Next catalyst
- None dated
What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $44.42entry
- T+1 · 3mo ago −2.03%α −2.64% · $43.52
- T+5 · 3mo ago −2.79%α −4.00% · $43.18
- T+20 · 3mo ago −5.56%α −6.16% · $41.95
- T+60 · 18d ago −12.43%α −10.76% · $38.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12.2% miss vs consensus of $-0.47, with no revenue. The quarter was dominated by the July 2026 completion of the sevasemten sale to Servier for $1.55B upfront (up to $2.65B total), transforming the balance sheet to a pro-forma $2.01B cash position and pivoting the company to a pure-play cardiovascular focus. Positive Phase 2 CIRRUS-HCM data for EDG-7500 supports a planned Phase 3 start in Q4 2026, but the company remains pre-revenue with widening operating losses as it funds the new pipeline.
Key Financial Metrics
Key Facts
- Net loss per share was $-0.53 for Q2 2026, compared to $-0.34 in Q2 2025, a 55.9% YoY increase in net loss.
- EPS of $-0.53 missed consensus of $-0.47 by 12.2%.
- Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront cash (up to $2.65B total) in July 2026.
- Pro-forma cash balance post-sale is approximately $2.01B before taxes and transaction costs, up from $460.7M at quarter-end.
- Positive 12-week Phase 2 CIRRUS-HCM data for EDG-7500 announced; Phase 3 initiation expected in Q4 2026.
- R&D expenses rose 41.7% YoY to $47.5M, driven by EDG-7500, EDG-15400, and MESA extension study activity.
- Company has no revenue and is transitioning to a cardiovascular-focused biopharmaceutical company.
Financial Impact
Q2 net loss of $57.3M widened 58.7% YoY from $36.1M; pro-forma cash of ~$2.01B post-Servier deal provides >8 years of runway at current burn rate.
Risk Factors
- Single-asset dependency on EDG-7500 for HCM, with no approved products or revenue.
- Phase 3 clinical risk for EDG-7500; positive Phase 2 data may not replicate.
- Operating losses are widening as R&D spend increases for the cardiovascular pipeline.
- No guarantee of receiving the $1.1B in milestone payments from Servier.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091671 |
| Document: tm2621653d1_8k.htm | 0001104659-26-091671 |
| Document: 0001104659-26-091671-index-headers.html | 0001104659-26-091671 |
| Document: 0001104659-26-091671-index.html | 0001104659-26-091671 |
| Document: 0001104659-26-091671.txt | 0001104659-26-091671 |
| 8-K Data (Synthetic) | 0001104659-26-091671 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Viewing Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers